Reported cases of MDS/acute leukemia by WHO criteria in patients with Ph-negative clones treated with imatinib
Reference . | Ph-cytogenetics . | Diagnosis . | Characteristics . | Previous treatment . |
|---|---|---|---|---|
| Current report, patient 2 | –7 | AML | — | IFN/cytarabine, HU, imatinib, AMN-107 |
| Perel et al20 | Complex*† | AML | No dysplastic features | IFN/imatinib |
| Chee et al18 | Complex* | AML | — | HU, IFN, BMT, DLI, imatinib |
| Current report, patient 1 | –7 | MDS (RAEB-2) → AML | — | HU, imatinib |
| Current report, patient 3 | Complex | MDS (RAEB-2) → AML | — | IFN/cytarabine, imatinib |
| Perel et al20 | –7 | MDS/AML (> 20% blasts) | No dysplastic features | IFN/imatinib |
| Bacher et al21 | –7 | MDS (RAEB-2) | — | IFN/cytarabine, HU, imatinib |
| Patchenko et al15 | +8 | MDS (RAEB-2) | Spontaneous improvement in dysplastic changes? | HU, imatinib |
| Bacher et al21 | –7 | MDS (RARS) | — | Busulfan, IFN, HU, imatinib |
| Meuss et al22 | –7, +8 | MDS | RA | IFN, auto BMT, imatinib |
| Bumm et al14 | –7 | MDS | Severe dysplasia | HU, IFN, imatinib |
| Bumm et al14 | t(3,21) | MDS | 10% blasts | Ida/cytarabine, HU, IFN, imatinib |
| Mozziconacci et al23 | 5q-/7q- | MDS | — | IFN, ROAP, auto BMT, imatinib |
| O'Dwyer et al24 | inv(1)(p32.3p31.2),del(10)(q22q22) | MDS | 7% blasts | IFN, imatinib |
| Alimena et al17 | +8 | MDS | — | HU, imatinib |
| Jin Huh et al25 | Diploid | ALL | — | HU, IFN, imatinib |
| Cherrier-De Wilde et al19 | Diploid | ALL | — | HU, IFN, imatinib |
Reference . | Ph-cytogenetics . | Diagnosis . | Characteristics . | Previous treatment . |
|---|---|---|---|---|
| Current report, patient 2 | –7 | AML | — | IFN/cytarabine, HU, imatinib, AMN-107 |
| Perel et al20 | Complex*† | AML | No dysplastic features | IFN/imatinib |
| Chee et al18 | Complex* | AML | — | HU, IFN, BMT, DLI, imatinib |
| Current report, patient 1 | –7 | MDS (RAEB-2) → AML | — | HU, imatinib |
| Current report, patient 3 | Complex | MDS (RAEB-2) → AML | — | IFN/cytarabine, imatinib |
| Perel et al20 | –7 | MDS/AML (> 20% blasts) | No dysplastic features | IFN/imatinib |
| Bacher et al21 | –7 | MDS (RAEB-2) | — | IFN/cytarabine, HU, imatinib |
| Patchenko et al15 | +8 | MDS (RAEB-2) | Spontaneous improvement in dysplastic changes? | HU, imatinib |
| Bacher et al21 | –7 | MDS (RARS) | — | Busulfan, IFN, HU, imatinib |
| Meuss et al22 | –7, +8 | MDS | RA | IFN, auto BMT, imatinib |
| Bumm et al14 | –7 | MDS | Severe dysplasia | HU, IFN, imatinib |
| Bumm et al14 | t(3,21) | MDS | 10% blasts | Ida/cytarabine, HU, IFN, imatinib |
| Mozziconacci et al23 | 5q-/7q- | MDS | — | IFN, ROAP, auto BMT, imatinib |
| O'Dwyer et al24 | inv(1)(p32.3p31.2),del(10)(q22q22) | MDS | 7% blasts | IFN, imatinib |
| Alimena et al17 | +8 | MDS | — | HU, imatinib |
| Jin Huh et al25 | Diploid | ALL | — | HU, IFN, imatinib |
| Cherrier-De Wilde et al19 | Diploid | ALL | — | HU, IFN, imatinib |